Galilcon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 50.00 K
- Company Age 5 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -18.00%
- Ebitda -22.50%
- Net Worth -249.72%
- Total Assets %
About Galilcon Pharmaceuticals
Galilcon Pharmaceuticals Private Limited (GPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 February 2019 (Five years and 11 months 12 days old ). Its registered office is in Thane, Maharashtra.
The Company is engaged in the Service Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 50.00 K , as per Ministry of Corporate Affairs (MCA) records.
Jay Choudhary, John Godfrey, Vinay Choudhary, and One other member serve as directors at the Company.
Company Details
-
LocationThane, Maharashtra
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U93000MH2019PTC321545
-
Company No.
321545
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Feb 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Galilcon Pharmaceuticals?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
John Godfrey
|
Director | 20-Feb-2019 | Current |
|
Jay Choudhary
|
Director | 20-Feb-2019 | Current |
|
Vinay Choudhary
|
Director | 25-May-2021 | Current |
|
Shakun Choudhary
|
Director | 28-Mar-2023 | Current |
Financial Performance of Galilcon Pharmaceuticals.
Galilcon Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 18% decrease in profit. The company's net worth observed a substantial decline by a decrease of 249.72%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Galilcon Pharmaceuticals?
Unlock access to Galilcon Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Galilcon Pharmaceuticals?
Unlock and access historical data on people associated with Galilcon Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Galilcon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Galilcon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.